Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CSLLY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CSLLY and 80,000+ other tickers.
See exactly how CSLLY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CSLLY and 80,000+ other tickers.
CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies…
CSL Limited (CSLLY) Q4 2026 Earnings Call Transcript
Australia's CSL on Tuesday posted a 2% fall in annual profit, dragged by declining revenue at its core plasma division.
Carlisle tops Q2 earnings and revenue estimates, posts record sales and raises its 2026 outlook as organic growth supported both reporting segments.
Australian biotechnology firm CSL said on Wednesday it would start clinical trials to support regulatory approval for a new manufacturing process aimed at lifting immunoglobulin output from the same amount of plasma.
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress KING OF PRUSSIA, Pa., July 27, 2026 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE).